PCH
MNPR icon

Polar Capital Holdings’s Monopar Therapeutics MNPR Stock Holding History

Polar Capital Holdings’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Sell
214,469
-12,057
-5% -$746K 0.05% 169
2026
Q1 		$12.4M Buy
226,526
+120,776
+114% +$7.3M 0.04% 173
2025
Q4 		$6.91M Buy
+105,750
New +$8.64M 0.03% 217

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Polar Capital Holdings's MNPR Position: Q2 2026 in Review

Polar Capital Holdings reduced its Monopar Therapeutics (MNPR) stake by 5.3% in Q2 2026, selling an estimated $746K and leaving 214,469 shares worth $19.9M. The position accounts for 0.05% of the portfolio, ranked #169.

Polar Capital Holdings first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Polar Capital Holdings held 214,469 shares of Monopar Therapeutics worth $19.9M as of Q2 2026.
  • Polar Capital Holdings sold 12,057 Monopar Therapeutics shares in Q2 2026, an estimated $746K.
  • Monopar Therapeutics made up 0.05% of Polar Capital Holdings's portfolio in Q2 2026, its #169 holding.
  • Polar Capital Holdings first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.